125 Participants Needed

Cholesterol-Lowering Drugs for Type 1 Diabetes

(CHORD1 Trial)

Recruiting at 3 trial locations
IG
ZF
Overseen ByZahi Fayad
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using certain medications like antithrombotic therapy, aspirin, NSAIDs, or PCSK9 inhibitors.

What data supports the effectiveness of the drugs used in the clinical trial for cholesterol-lowering in type 1 diabetes?

Research shows that atorvastatin, a drug used in the trial, not only lowers cholesterol but may also help preserve some insulin-producing cells in people newly diagnosed with type 1 diabetes. Additionally, ezetimibe and evolocumab, other drugs in the trial, are effective in lowering bad cholesterol (LDL-C) and reducing heart disease risk, which is beneficial for managing diabetes-related complications.12345

Is it safe to use cholesterol-lowering drugs like Atorvastatin, Evolocumab, and Ezetimibe in humans?

Cholesterol-lowering drugs such as Atorvastatin, Evolocumab, and Ezetimibe have been studied for safety in humans. Common side effects of statins like Atorvastatin include muscle symptoms and a risk of new-onset diabetes, but these do not outweigh the benefits. Evolocumab and Ezetimibe are generally safe, with Evolocumab being used for patients with high cholesterol not controlled by other drugs, and Ezetimibe showing no significant interactions with most other medications.16789

How does the drug combination of Atorvastatin, Evolocumab, and Ezetimibe differ from other treatments for type 1 diabetes?

This drug combination is unique because it targets cholesterol management in type 1 diabetes, which is not commonly addressed. Atorvastatin may help preserve beta cell function, while Ezetimibe and Evolocumab are effective in lowering cholesterol absorption and LDL levels, respectively, offering a comprehensive approach to reducing cardiovascular risk in these patients.23101112

What is the purpose of this trial?

This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question.This study will recruit 125 participants with Type 1 Diabetes (T1D) to:1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.

Research Team

IG

Ira Goldberg, MD

Principal Investigator

NYU Langone Health

Eligibility Criteria

This trial is for adults aged 18 to 89 with Type 1 Diabetes and LDL cholesterol over 100mg/dl. They must have a confirmed diagnosis of T1D, not be pregnant, and cannot have been hospitalized or had an infection in the last month. Participants should not be on aspirin, NSAIDs within the past three days, immunosuppressives, antithrombotics, or PCSK9 inhibitors.

Inclusion Criteria

I have been diagnosed with diabetes based on blood sugar or A1C levels.
Your LDL cholesterol is higher than 100 milligrams per deciliter.
You have a history of type 1 diabetes, including a specific type called latent autoimmune diabetes of adulthood.
See 2 more

Exclusion Criteria

I have taken NSAID medication in the last 3 days.
You have low hemoglobin or platelet levels in your blood.
I am on medication to prevent blood clots due to heart disease.
See 11 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive weekly injections of PCSK9i (evolocumab) and daily oral pills of atorvastatin or ezetimibe for 1 month

4 weeks
1 visit (in-person) at baseline, 1 self-administered injection at 2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Atorvastatin Calcium Tablets
  • Evolocumab Cartridge
  • Ezetimibe Tablets
Trial Overview The study tests how lowering cholesterol affects platelet function (which helps blood clot), White Blood Cell gene expression (important for fighting infections), and blood vessel function in people with Type 1 Diabetes using Evolocumab Cartridge combined with Atorvastatin Calcium Tablets or Ezetimibe Tablets.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: 4-Week LDL-Cholesterol (LDL-C)-Reduction TreatmentExperimental Treatment7 Interventions
Treatment consists of: Evolocumab (140 mg; 2 injections, one administered at baseline visit and another self-administered 2 weeks later), and; Atorvastatin (up to 80mg dose; 1 tab per day for 30 days, starting at baseline visit post-assessment). Participants with statin intolerance will be provided with a 1-month supply of ezetimibe 10 mg to replace Evolocumab and Atorvastatin. * Additional procedures: Blood draws. * Optional procedures: Glycocalyx testing, PET/CT, or Endothelial Cell Collection.

Atorvastatin Calcium Tablets is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

🇪🇺
Approved in European Union as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease
🇺🇸
Approved in United States as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease
  • Homozygous familial hypercholesterolemia
🇨🇦
Approved in Canada as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease
🇯🇵
Approved in Japan as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease
🇨🇳
Approved in China as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease
🇨🇭
Approved in Switzerland as Lipitor for:
  • Hypercholesterolemia
  • Mixed dyslipidemia
  • Prevention of cardiovascular disease

Find a Clinic Near You

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials
1,431
Recruited
838,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

Statin drugs effectively lower LDL-cholesterol and reduce cardiovascular risk, but can cause side effects like muscle symptoms and diabetes, which do not outweigh their benefits.
Evolocumab, a PCSK9 inhibitor, is an effective treatment for patients with familial hypercholesterolemia who do not respond adequately to statins or ezetimibe, highlighting the importance of tailored lipid therapy based on individual patient needs.
An updated review of lipid-modifying therapy.Simons, LA.[2020]
In a study involving 89 patients with newly diagnosed type 1 diabetes, atorvastatin did not significantly preserve beta cell function compared to placebo over 18 months, although there was a nonsignificant slower decline in beta cell function in the atorvastatin group.
Atorvastatin treatment resulted in significant reductions in total cholesterol and C-reactive protein levels, indicating its effectiveness in lipid-lowering and anti-inflammatory effects, but metabolic control remained similar between both groups.
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.Martin, S., Herder, C., Schloot, NC., et al.[2022]
In a study comparing the effects of simvastatin and ezetimibe on cholesterol levels, simvastatin was significantly more effective in lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes (T2DM) than in those with type 1 diabetes (T1DM).
Ezetimibe, a cholesterol absorption inhibitor, was found to be more effective than simvastatin in lowering LDL-C levels in T1DM patients, suggesting that cholesterol absorption inhibitors may be a better treatment option for this group.
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.Ciriacks, K., Coly, G., Krishnaswami, S., et al.[2015]

References

An updated review of lipid-modifying therapy. [2020]
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. [2022]
Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus. [2015]
Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. [2023]
Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe. [2022]
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome. [2022]
Ezetimibe for hypercholesterolemia. [2015]
Ezetimibe--a new approach in hypercholesterolemia management. [2020]
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Treatment of lipid disorders in patients with diabetes. [2020]
Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes. [2023]
Dyslipidemia Management in Adults With Diabetes. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security